Adenosine is an endogenous nucleoside occurring in all cells of the body.
Adenosine injection is indicated for the following.
Conversion to sinus rhythm of paroxysmal supraventricular tachycardia (PSVT), including that associated with accessory bypass tracts (Wolff-Parkinson-White Syndrome). When clinically advisable, appropriate vagal maneuvers (e.g., Valsalva maneuver), should be attempted prior to adenosine administration.
It is important to be sure the adenosine solution actually reaches the systemic circulation (see
DOSAGE AND ADMINISTRATION).
Adenosine does not convert atrial flutter, atrial fibrillation, or ventricular tachycardia to normal sinus rhythm. In the presence of atrial flutter or atrial fibrillation, a transient modest slowing of ventricular response may occur immediately following adenosine administration.
Published Studies Related to Adenosine
The effect of PDRN, an adenosine receptor A2A agonist, on the healing of chronic
diabetic foot ulcers: results of a clinical trial. 
ulcer healing in patients with diabetes... CONCLUSIONS: PDRN facilitates the healing of Wagner 1 or 2 diabetic foot ulcers.
Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate
lyase and adenosine monophosphate-activated protein kinase in patients with
hypercholesterolemia: results of a multicenter, randomized, double-blind,
placebo-controlled, parallel-group trial. 
treating hypercholesterolemia and other cardiometabolic risk factors... CONCLUSIONS: ETC-1002 significantly lowered LDL-C levels up to 27% across a broad
The new oral adenosine A1 receptor agonist capadenoson in male patients with
stable angina. 
capadenoson in patients with stable angina... CONCLUSIONS: In patients with stable angina capadenoson lowers exercise HR at
Treatment of Unexplained Syncope: A Multicenter, Randomized Trial of Cardiac Pacing Guided by Adenosine 5'-triphosphate Testing. [2011.11.15]
CONCLUSIONS: This study suggests that, in elderly patients with SUO and positive ATP tests, active dual-chamber pacing reduces syncope recurrence risk by 75% (95% CI 44% to 88%). CLINICAL TRIAL REGISTRATION INFORMATION: http://www.controlled-trials.com/ISRCTN00029383; Unique Identifier: ISRCTN00029383.
Adenosine A2(A) receptor gene polymorphism (1976C>T) affects coronary flow reserve response during vasodilator stress testing in patients with non ischemic-dilated cardiomyopathy. [2011.08]
OBJECTIVES: Patients with non ischemic-dilated cardiomyopathy (DCM) are characterized by an activation of the adenosinergic system and reduced coronary flow reserve (CFR) evaluated by transthoracic Doppler echocardiography during vasodilator adenosinergic stress (dipyridamole administration). The aim of this study was to assess whether genetic polymorphisms (263C>T and 1976C>T) of the A2(A) receptor gene affect CFR response in patients with DCM... CONCLUSION: These data demonstrate that A2(A) 1976C>T polymorphism is associated with a blunted coronary vasodilatory response in patients with DCM, and support a direct consequences of this single nucleotide polymorphism for protein expression. Additional studies are needed to better define the functional role of this genetic variant as well as to clarify the potential clinical impact of genetics during pharmacological stress cardiac imaging.
Clinical Trials Related to Adenosine
Myocardial Protection With Adenosine Preconditioning [Completed]
Adenosine has been proved to be an important mediator of myocardial protection induced by
ischemic preconditioning. The hypothesis of this study is that adenosine preconditioning can
provide additional myocardial protection in the setting of pediatric open heart surgery with
cardioplegia and cardiopulmonary bypass.
Effect of Ticagrelor vs. Dipyridamole on Adenosine Uptake [Active, not recruiting]
The investigators are trying to determine if a single dose of Ticagrelor will increase
delivery of intraarterially-infused adenosine into the forearm interstitium, consistent with
adenosine reuptake blockade.
Analysis of Adenosine on Sinus and Atrioventricular Nodal Conduction in the Pediatric Transplanted Heart [Not yet recruiting]
Heart transplants save the lives of nearly 500 children in heart failure per year. Columbia
is one of the largest pediatric heart transplant centers in the world, averaging 25
transplants per year, and providing ongoing care to nearly 250 children with transplanted
hearts. After transplant, children are at increased risk to develop sudden onset of
abnormally fast heart rates. This research project will study adenosine, a medication that
is routinely used to slow fast heart rates in non-transplanted children (i. e. normal
hearts), and its effects on the transplanted heart. Adenosine is often not used in patients
with transplanted hearts because, based on prior limited research in adult patients, the
standard adult dose may have a longer medication effect, producing a slower heart rate for
an undesirable period of time. However, the current alternatives to adenosine treatment are
either inappropriate for the pediatric age range, or have increased risk of unwanted side
effects. This research project will answer two questions: is adenosine safe to give a child
who has had a heart transplant, and will it be effective in treating the fast heart rate?
All pediatric heart transplant patients undergo regular heart testing, known as a cardiac
catheterization, one or more times per year. Three days before testing, participants will
be asked to stop a regular medication, dipyridamole, because it slows the breakdown of
adenosine in the body, and may increase its effects. (Of note, all patients that are on
dipyridamole are also on aspirin, which gives a second line of heart protection, and will
not be stopped.) After regular cardiac catheterization, all patients will already have
intravenous (IV) access to give medication. Also, this setting allows the opportunity to
have a back-up pacing catheter in the heart, ensuring that there will not be a longer than
desired effect from the medication. Adenosine will be given per a low-dose protocol until
either the medication effect is seen or the maximum dose is reached. There will be no
difference in procedure recovery period time, and patients will resume regular home
medications after finishing the test. As Columbia is one of largest pediatric heart
transplant centers in the world, studying the effects of adenosine at low doses will benefit
the investigators population greatly, either to find a new recommended medication dose, or
to provide evidence that this medication is truly inadvisable for the investigators
Regadenoson to Achieve Maximal Hyperemia for Fractional Flow Reserve in the Catheterization Lab [Recruiting]
The purpose of this study is to determine if regadenoson is as safe and effective as
adenosine when used in the cardiac catheterization lab during measurement of coronary flow
reserve and fractional flow reserve. The study hypothesis is the assessment of Fractional
Flow Reserve (FFR) in the catheterization lab can be performed with equivalent accuracy when
hyperemia is induced with IV Regadenoson compared with IV Adenosine without compromising
AMP as a Better Delivery System of Adenosine [Suspended]
Adenosine and AMP are substances normally present in the body. Adenosine is also given for
the treatment of some heart rhythm problems and may be used to reduce heart damage during
heart attacks. The problem in using adenosine is that it is taken up by cells and,
therefore, very little of the adenosine we give by vein or in the artery actually reaches
the tissue. We propose to use AMP as a way to improve delivery of adenosine. AMP is
inactive by itself, but is converted to adenosine in tissue. We hope that by giving AMP we
will increase levels of adenosine in tissue. To see if this is true, we will give either
adenosine or AMP into the forearm artery while we measure how much adenosine reaches the
Reports of Suspected Adenosine Side Effects
Arteriospasm Coronary (9),
Cardiac Arrest (5),
Drug Ineffective (3),
Loss of Consciousness (3),
Livedo Reticularis (3), more >>
Page last updated: 2014-11-30